Lee, K., Welton, N., Shah, A.S., Adamson, P., Dias, S., Anand, A., Newby, D.E., Mills, N.L. and McAllister, D.A. (2018) Differences in relative and absolute effectiveness of oral P2Y12 inhibition in men and women: a meta-analysis and modelling study. Heart, 104(8), pp. 657-664. (doi: 10.1136/heartjnl-2017-312003) (PMID:28982722) (PMCID:PMC5890639)
|
Text
146868.pdf - Published Version Available under License Creative Commons Attribution. 1MB |
Abstract
Objective: To estimate the absolute treatment effects of newer P2Y12 inhibitors (ticagrelor and prasugrel) compared with clopidogrel in men and women with acute coronary syndrome (ACS). Methods: We searched Ovid MEDLINE, Embase and the Cochrane Central Register of Controlled Trials for randomised controlled trials of oral P2Y12 inhibitors for acute stroke or ACS. Age-specific and sex-specific mortality was obtained for all patients admitted to hospital with myocardial infarction in Scotland from 2006 to 2010 (prior to introduction of prasugrel or ticagrelor). Results: From 9277 articles, nine fulfilled our inclusion criteria. Three trials compared newer P2Y12 inhibitors to clopidogrel in ACS, in which the treatment rate ratio (RR) for major adverse cardiovascular events in men was 0.80 (95% CI 0.69 to 0.93). For the same outcome, across all nine trials, the sex–treatment interaction RR was 1.08 (95% CI 0.98 to 1.19). Combining these estimates yielded a treatment RR in women of 0.86 (95% CI 0.72 to 1.04). 17 842 women and 27 818 men were admitted to hospital with myocardial infarction. Mortality was higher for women than men for all-cause (5708, 32.0% vs 5891, 21.2%), cardiovascular (4032, 22.6% vs 4117, 14.8%) and bleeding (193, 1.1% vs 228, 0.8%) deaths. On applying the sex-specific RRs to this population, the absolute risk reduction for mortality at 1 year was similar for women and men for all-cause (2.30% (95% CI −0.92% to 5.22%) vs 2.47% (95% CI 0.62% to 4.10%)), cardiovascular (2.70% (95% CI −0.63% to 5.74%)) vs 2.72% (95% CI 0.92% to 4.35%)) and bleeding (−0.27% (95% CI −1.06% to 0.30%) vs −0.18% (95% CI −0.71% to 0.24%)) deaths. Conclusion: Newer P2Y12 inhibitors may be slightly less efficacious in women than men, but the absolute risk reduction is similar in both sexes.
| Item Type: | Articles |
|---|---|
| Status: | Published |
| Refereed: | Yes |
| Glasgow Author(s) Enlighten ID: | McAllister, Professor David and Newby, Professor David |
| Authors: | Lee, K., Welton, N., Shah, A.S., Adamson, P., Dias, S., Anand, A., Newby, D.E., Mills, N.L., and McAllister, D.A. |
| College/School: | College of Science and Engineering > School of Engineering > Autonomous Systems and Connectivity |
| Journal Name: | Heart |
| Publisher: | BMJ Publishing Group |
| ISSN: | 1355-6037 |
| ISSN (Online): | 1468-201X |
| Published Online: | 05 October 2017 |
| Copyright Holders: | Copyright © 2017 The Authors |
| First Published: | First published in Heart 2017 |
| Publisher Policy: | Reproduced under a Creative Commons license |
University Staff: Request a correction | Enlighten Editors: Update this record
Funder and Project Information
Funder and Project Information